Suppr超能文献

一种用于在低温条件下保存造血干细胞和祖细胞的可注射溶液。

An Injectable Solution for Preservation of Hematopoietic Stem and Progenitors Cells in Hypothermic Condition.

作者信息

Chevaleyre Jean, Rodriguez Laura, Attebi Esther, Duchez Pascale, Ivanovic Zoran

机构信息

Etablissement Français du Sang Nouvelle Aquitaine, CS21010, Bordeaux-Cedex, 3035, France.

U1211 MRGM Inserm/université de Bordeaux, Bordeaux, France.

出版信息

Stem Cell Rev Rep. 2025 Jan;21(1):96-106. doi: 10.1007/s12015-024-10829-w. Epub 2024 Dec 12.

Abstract

To ensure the preservation of functional hematopoietic stem cells (HSC) and committed progenitor cells (HPC) at + 4 °C in ex vivo expanded cord blood cell products during worldwide transportation and subsequent infusion-without the need for washing and cell concentration-we developed a conservation medium called Stabilizer of Expanded Cells (SEC), composed exclusively of injectable pharmacological products. The in vivo engraftment assay in immunodeficient mice was used to detect primitive HSCs before and after preservation at + 4 °C. In some experiments, a complex phenotype based on CD34, CD38, and CD133 expression was utilized for this purpose. Committed progenitors (CFU-GM, BFU-E, and CFU-Mix) were detected using methylcellulose culture colony-forming assays. Additionally, in some cases, the energetic metabolism (mitochondrial respiration) was evaluated using Seahorse technology. SEC was able to preserve the functionality of HSCs and HPCs in ex vivo expanded cell populations at + 4 °C for at least 48 h. Furthermore, SEC is also effective in fully preserving HSCs and HPCs in cytapheresis products for at least 72 h. Additionally, SEC enabled the full preservation of HSCs and HPCs for 72 h in freshly collected cord blood, maintaining a normal metabolic profile of CD34 cells. The SEC medium exhibits a positive effect on the maintenance of both HSCs and HPCs at + 4 °C, regardless of their source. Therefore, SEC can be applied in cell therapy protocols based on HSCs and HPCs with a significant advantage: the product does not need to be washed and concentrated before injection into the patient.

摘要

为确保在全球运输及后续输注过程中,体外扩增的脐血细胞产品中的功能性造血干细胞(HSC)和定向祖细胞(HPC)能在 +4°C 保存,且无需洗涤和细胞浓缩,我们研发了一种名为扩增细胞稳定剂(SEC)的保存培养基,其仅由可注射的药物产品组成。利用免疫缺陷小鼠体内移植试验检测 +4°C 保存前后的原始 HSC。在一些实验中,基于 CD34、CD38 和 CD133 表达的复杂表型用于此目的。使用甲基纤维素培养集落形成试验检测定向祖细胞(CFU - GM、BFU - E 和 CFU - Mix)。此外,在某些情况下,使用 Seahorse 技术评估能量代谢(线粒体呼吸)。SEC 能够在 +4°C 下将体外扩增细胞群体中的 HSC 和 HPC 的功能保存至少 48 小时。此外,SEC 在全血单采产品中至少 72 小时内也能有效完全保存 HSC 和 HPC。另外,SEC 能在新鲜采集的脐血中将 HSC 和 HPC 完全保存 72 小时,维持 CD34 细胞的正常代谢谱。无论其来源如何,SEC 培养基在 +4°C 下对 HSC 和 HPC 的维持均表现出积极作用。因此,SEC 可应用于基于 HSC 和 HPC 的细胞治疗方案,具有显著优势:产品在注入患者前无需洗涤和浓缩。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验